Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell cycle risk score

Sanjeev Kaul, Kirk J. Wojno, Steven Stone, Brent Evans, Ryan Bernhisel, Stephanie Meek, Richard E. D'Anna, Jeffrey Ferguson, Jeffrey Glaser, Todd M. Morgan, Jeremy Lieb, Robert Yan, Todd Cohen, Behfar Ehdaie

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Aim: To evaluate active surveillance (AS) selection, safety and durability among men with low-risk prostate cancer assessed using the clinical cell cycle risk (CCR) score, a combined clinical and molecular score. Patients & methods: Initial treatment selection (AS vs treatment) and duration of AS were evaluated for men with low-risk prostate cancer according to the CCR score and National Comprehensive Cancer Network guidelines. Adverse events included biochemical recurrence and metastasis. Results: 82.4% (547/664) of men initially selected AS (median follow-up: 2.2 years), 0.4% (2/547) of whom experienced an adverse event. Two-thirds of patients remained on AS for more than 3 years; patient choice was the most common reason for leaving AS. Conclusion: The CCR score may aid in the identification of men who can safely defer prostate cancer treatment.

Original languageEnglish
Pages (from-to)491-499
Number of pages9
JournalPersonalized Medicine
Volume16
Issue number6
DOIs
StatePublished - 2019

Keywords

  • active surveillance
  • molecular score
  • prostate cancer
  • risk assessment
  • survival

Fingerprint

Dive into the research topics of 'Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell cycle risk score'. Together they form a unique fingerprint.

Cite this